normative

Hard Clinical Endpoints Must Prove CGM Value to Payers

To justify a low-cost product to insurers, Dexcom needs hard endpoints such as fewer hospitalizations and surgeries, and savings from reducing unnecessary drugs, since a CGM can reveal that a GLP-1 is ineffective and a cheaper drug is warranted.

normativepending

Speaker

Aneal

Evidence Quote

“A CGM will tell you if, for example, your GLP-1 is not particularly effective and you need to come off that drug”

Source

Dexcom: Digitizing Diabetes Management— Business Breakdowns
Created: 11/20/2026, 5:18:27 AM

Your notes

Loading notes...